Continuous Access to Advanced and Metastatic Renal Cell Carcinoma Therapy With Everolimus Post Pazopanib Treatment.

Trial Profile

Continuous Access to Advanced and Metastatic Renal Cell Carcinoma Therapy With Everolimus Post Pazopanib Treatment.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Everolimus (Primary) ; Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms CATChEz
  • Sponsors Novartis
  • Most Recent Events

    • 04 Oct 2017 Last checked against ClinicalTrials.gov record.
    • 26 Sep 2017 Status changed from active, no longer recruiting to discontinued.
    • 01 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top